References
- Kim J, Yu Y. A psychological approach on impulse control disorder criminal. Korean Crim Psychol Rev 2015;11(3):53-76.
- Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry 2012;27(2):160-6. https://doi.org/10.1002/gps.2704
- Callesen MB, Scheel-Kruger J, Kringelbach ML, Moller A. A systematic review of impulse control disorders in Parkinson's disease. J Parkinsons Dis 2013;3(2):105-38. https://doi.org/10.3233/JPD-120165
- Molde H, Moussavi Y, Kopperud ST, Erga AH, Hansen AL, Pallesen S. Impulse-control disorders in Parkinson's disease: a meta-analysis and review of case-control studies. Front Neurol 2018;9:330. https://doi.org/10.3389/fneur.2018.00330
- Gatto EM, Aldinio V. Impulse control disorders in Parkinson's disease. A brief and comprehensive review. Front Neurol 2019;10:351. https://doi.org/10.3389/fneur.2019.00351
- Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63(7):969-73. https://doi.org/10.1001/archneur.63.7.969
- Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015;69(4):183-9. https://doi.org/10.1002/syn.21805
- Rizos A, Sauerbier A, Antonini A, et al. A european multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 2016;23(8):1255-61. https://doi.org/10.1111/ene.13034
- Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: A complex association. Drug Saf 2018;41(1):19-75. https://doi.org/10.1007/s40264-017-0590-6
- Schreiber L, Odlaug BL, Grant JE. Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front psychiatry. 2011;2:1. https://doi.org/10.3389/fpsyt.2011.00001
- Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: A synthesis of the literature. Sleep Med Rev 2012;16(4):283-95. https://doi.org/10.1016/j.smrv.2011.05.002
- Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;8(1):3-6. https://doi.org/10.1007/s11102-005-5079-0
- Sucharew H, Macaluso M. Methods for research evidence synthesis: The scoping review approach. J Hosp Med 2019;14(7):416-8. https://doi.org/10.12788/jhm.3248
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8(1):19-32. https://doi.org/10.1080/1364557032000119616
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45. https://doi.org/10.1038/clpt.1981.154
- Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011;11(1):117. https://doi.org/10.1186/1471-2377-11-117
- Bayard S, Langenier MC, Dauvilliers Y. Decision-making, rewardseeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep 2013;36(10):1501-7. https://doi.org/10.5665/sleep.3044
- Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? Neurology 2016;87(1):36-40. https://doi.org/10.1212/WNL.0000000000002803
- Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12(1):34-40. https://doi.org/10.1016/j.sleep.2010.08.005
- Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 2012;13(10):1280-5. https://doi.org/10.1016/j.sleep.2012.08.004
- Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med 2018;169(7):467-73. https://doi.org/10.7326/m18-0850
- Leeman RF, Potenza MN. Impulse control disorders in Parkinson's disease: clinical characteristics and implications. Neuropsychiatry (London) 2011;1(2):133-47. https://doi.org/10.2217/npy.11.11
- Kolla BP, Mansukhani MP, Barraza R, Bostwick JM. Impact of dopamine agonists on compulsive behaviors: A case series of pramipexole-induced pathological gambling. Psychosomatics 2010;51(3):271-3. https://doi.org/10.1016/S0033-3182(10)70695-2
- Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30(5):249-55. https://doi.org/10.1097/wnf.0b013e31804c780e
- Cornelinus J. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010;33(1):81-7.
- Mishima T, Fujioka S, Kurisaki R, et al. Impulse control disorders and punding in Perry syndrome. Parkinsonism Relat Disord 2015;21(11):1381-2. https://doi.org/10.1016/j.parkreldis.2015.09.037
- Tajima-Pozo K, Bardudo E, Aguilar-Shea AL, Papanti D. Paraphilia as adverse drug reaction to dopamine agonist (Pramipexole). Acta Neuropsychiatr 2011;23(2):89.
- Strejilevich SA, Martino DJ, Igoa A, Manes F. Pathological gambling in a bipolar patient treated with pramipexole. J Neuropsychiatry Clin Neurosci 2011;23(1)E2-3.
- Maruo J, Haraguchi Y, Tateishi H, et al. Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report. Psychogeriatrics 2016;16(4):283-6. https://doi.org/10.1111/psyg.12148
- Larson ER. Neuropsychological findings in a case of punding before and after cessation of pramipexole. Clin Neuropsychol 2015;29(1):166-78. https://doi.org/10.1080/13854046.2015.1005674
- Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91(3):e189-201. https://doi.org/10.1212/wnl.0000000000005816
- Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin Geriatr Med 2019;36(1):105-18.